What question did this study set out to answer?

This review assesses the evidence regarding the efficacy of tigecycline against multidrug-resistant Acinetobacter species.

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

View Full Paper

Ask AI

Bookmark

Authors

Review evaluates tigecycline's effectiveness against multidrug-resistant Acinetobacter infections, highlighting implications for treatment.

This review assesses the evidence regarding the efficacy of tigecycline against multidrug-resistant Acinetobacter species.
Evaluated microbiological activity and clinical outcomes through a search of PubMed articles.
Extracted data from 22 microbiological studies involving 2384 Acinetobacter spp. isolates and 8 clinical studies on tigecycline therapy.
Tigecycline exhibited at least 90% susceptibility in 9/18 studies for MDR Acinetobacter and 7/15 for carbapenem-resistant strains.
Out of 42 severe cases of Acinetobacter infections treated, tigecycline was effective in 32 cases, often used with other antibiotics.
Resistance to tigecycline emerged in 3 patients during therapy.

Karageorgopoulos et al. (2008) studied this question.

View Full Paper

Ask AI

Bookmark

Review evaluates tigecycline's effectiveness against multidrug-resistant Acinetobacter infections, highlighting implications for treatment.